UNITED STATES
                   SECURITIES AND EXCHANGE COMMISSION
                         WASHINGTON, D.C.  20549
                                FORM 10-Q
      [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

              For the quarterly period ended June 30, 1994

                                   OR

      [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934


                      Commission file number 1-5975

                               HUMANA INC.

         (Exact name of registrant as specified in its charter)

                 Delaware                                61-0647538
      (State or other jurisdiction of                 (I.R.S. Employer
      incorporation or organization)                 Identification No.)

500 West Main Street, Louisville, Kentucky                  40202
 (Address of principal executive offices)                (Zip Code)


                             (502) 580-1000
          (Registrant's telephone number, including area code)


                             Not Applicable
          (Former name, former address and former fiscal year,
                      if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange
Act of 1934 during the preceding 12 months, and (2) has been subject to
such filing requirements for the past 90 days.

                                                              
             YES       X                              NO               


Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.

                                                       Outstanding at
           Class of Common Stock                       August 8, 1994

             $.16 2/3 par value                      160,989,760 shares

                                                                         
                                 1 of 18


                               HUMANA INC.
                                FORM 10-Q
                              June 30, 1994




Page of Form 10-Q Part I: Financial Information Item 1. Financial Statements Consolidated Statement of Income for the quarters and six months ended June 30, 1994 and 1993 3 Condensed Consolidated Balance Sheet at June 30, 1994 and December 31, 1993 4 Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 1994 and 1993 5 Notes to Condensed Consolidated Financial Statements 6-7 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 8-14 Part II: Other Information Items 1 to 6 15-17 Exhibit Ratio of Earnings to Fixed Charges 18
2 HUMANA INC. CONSOLIDATED STATEMENT OF INCOME For the quarters and six months ended June 30, 1994 and 1993 Unaudited (Dollars in millions except per share results)
Quarter Six Months 1994 1993 1994 1993 Revenues: Premiums $897 $778 $1,750 $1,564 Interest 15 14 28 24 Other 5 3 8 5 Total revenues 917 795 1,786 1,593 Operating expenses: Medical costs 736 660 1,439 1,322 Selling, general and administrative 111 91 213 184 Depreciation and amortization 12 12 24 24 Unusual charge (a) 18 18 Total operating expenses 877 763 1,694 1,530 Income from operations 40 32 92 63 Interest expense (a) (28) 2 (27) 4 Income before income taxes 68 30 119 59 Provision for income taxes (a) 14 11 33 22 Net income (a) $ 54 $ 19 $ 86 $ 37 Earnings per common share (a) $.33 $.12 $ .53 $ .23 Shares used in earnings per share computation (000) 160,836 159,040 160,659 158,970 (a) 1994 second quarter and six-month results include the favorable effect of the settlement of tax disputes with the Internal Revenue Service partially offset by the write-down of a nonoperational asset. See Note (B).
See accompanying notes. 3 HUMANA INC. CONDENSED CONSOLIDATED BALANCE SHEET Unaudited (Dollars in millions except per share amounts)
June 30, December 31, 1994 1993 Assets Current assets: Cash and cash equivalents $ 307 $ 372 Marketable securities 465 427 Premiums receivable, less allowance for loss of $23 - June 30, 1994 and $17 - December 31, 1993 51 37 Deferred income taxes 67 129 Other 57 37 Total current assets 947 1,002 Property and equipment, net 317 300 Long-term marketable securities 402 335 Cost in excess of net tangible assets acquired 100 60 Other 55 34 Total assets $1,821 $1,731 Liabilities and Common Stockholders' Equity Current liabilities: Medical costs payable $ 528 $ 448 Trade accounts payable and accrued expenses 205 154 Unearned premium revenues 110 Income taxes payable 55 59 Total current liabilities 788 771 Long-term obligations 61 71 Total liabilities 849 842 Common stockholders' equity: Common stock, 16 2/3 cents par; authorized 300,000,000 shares; issued and outstanding 160,965,386 shares - June 30, 1994 and 160,343,788 shares - December 31, 1993 27 27 Other 945 862 Total common stockholders' equity 972 889 Total liabilities and common stockholders' equity $1,821 $1,731 See accompanying notes.
4 HUMANA INC. CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS For the six months ended June 30, 1994 and 1993 Unaudited (Dollars in millions)
1994 1993 Cash flows from operating activities: Net income $ 86 $ 37 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization 24 24 Deferred income taxes 48 3 Unusual charge 18 Changes in operating assets and liabilities (46) (101) Other 2 13 Net cash provided by (used in) operating activities 132 (24) Cash flows from investing activities: Purchase and disposition of property and equipment, net (11) (6) Acquisition of health plan assets (37) (5) Change in marketable securities (123) (19) Other investing activities (29) Net cash used in investing activities (200) (30) Cash flows from financing activities: Cash contribution from Galen 135 Other 3 (2) Net cash provided by financing activities 3 133 Increase (decrease) in cash and cash equivalents (65) 79 Cash and cash equivalents at beginning of period 372 233 Cash and cash equivalents at end of period $307 $312 Interest payments, (refunds) net $(20) $ 1 Income tax payments, (refunds) net (13) 15 See accompanying notes.
5 HUMANA INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited (A) Basis of Presentation The accompanying financial statements are presented in accordance with the requirements of Form 10-Q and consequently do not include all of the disclosures normally required by generally accepted accounting principles or those normally made in an annual report on Form 10-K. Accordingly, for further information, the reader of this Form 10-Q may wish to refer to Humana Inc.'s (the "Company") Form 10-K for the year ended December 31, 1993. The financial information has been prepared in accordance with the Company's customary accounting practices and has not been audited. In the opinion of management, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature. (B) Income Tax Settlement and Unusual Charge During the second quarter ended June 30, 1994, the Company settled certain income tax disputes with the Internal Revenue Service (the "IRS") and reduced the net book value of a nonoperational asset to its estimated fair value. As a result of the two separate events which are more fully described below, Humana's net income for the second quarter ending June 30, 1994 was increased by $17 million or $.10 per share. Income Tax Settlement The Company received $71 million in income tax refunds for the settlement of disputes with the IRS regarding the timing of medical claims deductions and the deductibility of intangible amortization for tax years 1988 through 1991. The Company had previously prepaid tax and interest for these issues for the 1988 and 1989 tax years to stop the accrual of interest on the disputed amounts. As a result of the settlement, the Company recognized a $29 million ($18 million or $.11 per share after tax) reduction of interest expense and a $10 million ($.06 per share) reduction of tax expense, both of which represented the cumulative effect from 1988 to present of amounts provided for the disputed items. The remainder of the refund reduced the deferred tax asset carried on the Company's balance sheet. Unusual Charge The Company reduced the net book value of a nonoperational asset to its estimated fair market value. As a result, the Company recorded a pretax charge totaling $18 million ($11 million or $.07 per share after tax). 6 Notes to Condensed Consolidated Financial Statements, continued Humana Inc. Unaudited (C) Subsequent Event On August 15, 1994, the Company received notification from the National Committee for Quality Assurance ("NCQA") that its South Florida health plan had been denied accreditation. The NCQA denial was based upon a site visit conducted in July 1993. In anticipation of the denial, the Company and the State of Florida (the "State") developed a corrective action process that Humana is implementing under the supervision of Florida's Agency for Health Care Administration. In additon to assisting in the development of the corrective action process, the State completed its own site visit of the South Florida plan in August 1994. The Health Care Financing Administration ("HCFA") has also undertaken an investigation of the South Florida plan. The Company expects no material effects on its operations as a result of the denial of accreditation by NCQA or the HCFA investigation. 7 Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Humana Inc. The Company offers managed health care products which integrate financing and management with the delivery of health care services through a network of providers who share financial risk or who have incentives to deliver cost-effective medical services. These products are marketed primarily through health maintenance organizations ("HMOs") and preferred provider organizations ("PPOs") that encourage, and in most HMO products require, use of contracting providers. HMOs and PPOs also control health care costs by various means including the use of utilization controls such as pre-admission approval for hospital inpatient services and pre- authorization of outpatient surgical procedures. The HMO and PPO products of Humana are primarily marketed to employer and other groups ("Commercial") and Medicare-eligible individuals. The products marketed to Medicare-eligible individuals are either HMO products that provide health care services which include all Medicare benefits and, in certain circumstances, additional health care services that are not included in Medicare benefits ("Medicare risk") or indemnity insurance policies that supplement Medicare benefits ("Medicare supplement"). Results of Operations Second Quarter Ended June 30, 1994 and 1993 The Company's premium revenues increased 15 percent to $897 million for the quarter ended June 30, 1994, compared to $778 million for the same period in 1993. The increase in premium revenues is attributable to same- store Commercial and Medicare risk membership gains, premium rate increases of 4.3 percent for the Commercial product and 4.2 percent for the Medicare risk product, and the February 28, 1994 acquisition of Group Health Association ("GHA"), an HMO located in Washington, D.C. GHA premium revenues during the second quarter of 1994 totaled $50 million. Same-store Commercial and Medicare risk membership gains for the quarter ended June 30, 1994, were 6,700 and 4,600, respectively and compare favorably to the membership declines in the same period a year ago (decreases of 800 and 400, respectively). For 1994, the Company anticipates that same-store Commercial and Medicare risk membership gains will range between 7 and 10 percent. Medicare supplement membership declined during the quarter ended June 30, 1994, continuing the decline which resulted from management's decision to increase premiums to more closely approximate competitive levels and to close certain markets. The medical loss ratio for the quarter ended June 30, 1994, was 81.9 percent compared to 84.8 percent for the same period in 1993. The loss ratio improvement was primarily due to decreased hospital utilization in both the Commercial and Medicare risk products and a reduction in the Medicare risk product's rate of growth for physician and other medical services costs. Patient days per thousand members decreased 7 percent to 271 days per thousand for the Commercial product and 12 percent to 1,388 days per thousand for the Medicare risk product. Additional improvements in hospital and other medical services costs are necessary to achieve further reductions in the medical loss ratio since premium rate increases in both the Commercial and Medicare risk products are expected to approximate 4 percent for the remainder of 1994. 8 Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Humana Inc. The administrative cost ratio was 13.6 percent and 13.1 percent for the quarters ended June 30, 1994 and 1993, respectively. The increase is the result of additional spending for the expansion of market service areas, costs associated with the acquisition of GHA, and increased marketing efforts. Additional development spending is anticipated for the remainder of 1994 as the Company continues its strategy of expanding into contiguous markets. The Company's income before income taxes totaled $68 million for the quarter ended June 30, 1994, compared to $30 million for the same period in 1993. Income before income taxes in 1994 includes $29 million related to the favorable settlement of tax disputes with the IRS and an $18 million charge related to the write-down of a nonoperational asset. Net income increased from $19 million or $.12 per share to $54 million or $.33 per share for the quarters ended June 30, 1993 and 1994, respectively. Included in the second quarter of 1994's net income is $17 million or $.10 per share related to the nonrecurring items described above. The prospective beneficial effect of these items will approximate $.04 per share and $.05 per share in 1994 and 1995, respectively. Six Months Ended June 30, 1994 and 1993 The Company's premium revenues increased 12 percent to $1.8 billion for the six months ended June 30, 1994 compared to $1.6 billion for the same period in 1993. The increase in premium revenues is attributable to same- store Commercial and Medicare risk membership gains of 95,300, premium rate increases of 3.7 percent for the Commercial product and 4.0 percent for the Medicare risk product, and the acquisition of GHA. GHA premium revenues, since the February 28, 1994 acquisition totaled $67 million. On a same-store basis, Commercial membership increased 57,100 during the six months ended June 30, 1994 compared to a decrease of 24,600 for the six months ended June 30, 1993. During this same period, Medicare risk membership increased 10,400 compared to an increase of 1,900 members in the same period a year ago. Medicare supplement membership declined during the six months ended June 30, 1994, continuing the decline which resulted from management's decision to increase premiums to more closely approximate competitive levels and to close certain markets. The medical loss ratio for the six months ended June 30, 1994 was 82.2 percent compared to 84.5 percent for the same period in 1993. The reduction was primarily attributable to continued improvement in hospital utilization in both the Commercial and Medicare risk products and a reduction in the rate of growth for physician and other medical services costs in the Medicare risk product. Patient days per thousand members relative to the same six months ended June 30, 1993, decreased 5 percent to 279 days per thousand for the Commercial product and 8 percent to 1,490 days per thousand for the Medicare risk product. Additional improvements in hospital and other medical services costs are necessary to achieve further reductions in the medical loss ratio since premium rate increases in both the Commercial and Medicare risk products are expected to approximate 4 percent for the remainder of 1994. 9 Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Humana Inc. The administrative cost ratio was 13.5 percent and 13.3 percent for the six months ended June 30, 1994 and 1993, respectively. The increase is a result of additional spending for the expansion of market service areas, costs associated with the acquisition of GHA, and increased marketing efforts. Additional development spending is anticipated for the remainder of 1994 as the Company continues its strategy of expanding into contiguous markets. The Company's income before income taxes totaled $119 million for the six months ended June 30, 1994 compared to $59 million for the six months ended June 30, 1993. Pretax income for 1994 includes $29 million related to the favorable settlement of tax disputes with the IRS and an $18 million charge related to the write-down of a nonoperational asset. Net income increased from $37 million or $.23 per share to $86 million or $.53 per share for the six months ended June 30, 1993 and 1994, respectively. Included in net income for the six months ended June 30, 1994, is $17 million or $.10 per share related to the nonrecurring items described above. The prospective beneficial effect of these items will approximate $.04 per share and $.05 per share in 1994 and 1995, respectively. Liquidity Cash provided by the Company's operations totaled $132 million for the six months ended June 30, 1994 compared to cash used by operations of $24 million for the six months ended June 30, 1993. The timing of the receipt of Medicare risk premiums reduced cash provided by operations by $110 million and $102 million for the six months ended June 30, 1994 and 1993, respectively. Excluding the effect of the timing of Medicare risk premiums, cash provided by operations was $242 million and $78 million for the six months ended June 30, 1994 and 1993, respectively. The increase in cash provided by operations was primarily attributable to increased net income, the settlement of the tax disputes with the IRS, and the timing of payments for medical costs and other payables. The Company's current assets exceeded current liabilities by $159 million and $231 million at June 30, 1994 and December 31, 1993, respectively. The reduction in net working capital is primarily attributable to Humana's policy of classifying unrestricted cash, cash equivalents and marketable securities as long-term to conform with their intended use. The Company's subsidiaries operate in states which require certain levels of equity and regulate the payment of dividends to the parent company. As a result, the Company's ability to use operating subsidiaries' cash flows is restricted to the extent that the subsidiaries' ability to pay dividends to its parent company requires regulatory approval. At June 30, 1994, the Company had approximately $300 million of unrestricted cash, cash equivalents and marketable securities compared to $247 million at December 31, 1993. Management believes that existing working capital, including the aforementioned unrestricted funds, cash flows from operations and the availability of the Company's $200 million line of credit will be sufficient to meet future liquidity needs. 10 Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Humana Inc. Capital Resources The Company's ongoing capital expenditures relate primarily to medical care facilities used by either employed or affiliated physicians as well as administrative facilities and related computer information systems necessary for activities such as claims processing, billing and collections, medical utilization review and customer service. Excluding acquisitions, planned capital spending in 1994 will approximate $45 million to $50 million compared to $28 million in 1993. The increase in 1994 capital spending relates primarily to the refurbishing and equipping of the Company's staff model primary care facilities, including those located in Washington D.C. Management believes that its capital spending program is adequate to expand, improve and equip its existing business. Other Information The Company provides medical services to Medicare risk members under contracts with the Health Care Financing Administration ("HCFA") that are renewed for a one-year term each December 31 unless terminated 90 days prior thereto. The loss of these contracts or significant changes in the program, including reductions in payments or increases in benefits without corresponding increases in payments, would have a material adverse effect on the revenues, profitability and business prospects of the Company. HCFA's Office of the Actuary recently announced the projected national average rate of increase for 1995 under these contracts to be 7.9 percent. The final rate of increase for 1995 will be announced September 7, 1994. When the final rate increase is determined, geographic and other adjustments could significantly affect the Company's actual 1995 increase. Congress is in the process of evaluating a number of legislative proposals that would effect major changes in the United States health care system. Legislative reform is not anticipated before the latter part of 1994 and implementation of any reform package could take several additional years. In general, managed care is being considered as a means by which health care costs may be reduced. At this time, it is not possible to predict the final form these proposals will take or the effect these proposals may have on the Company, although management believes the Company is well positioned to take advantage of the opportunities which will be afforded by health care reform. In addition to federal reform, various states in which the Company operates have implemented or are in the process of implementing changes in the delivery of health care. Again, it is not possible to predict the final form these proposals will take or the effect these changes may have on the Company. Resolution of various loss contingencies, including litigation pending against the Company in the ordinary course of business, is not expected to have a material adverse effect on its financial position or results of operations. 11 Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Humana Inc.
1994 1993 Commercial members enrolled at: March 31 1,381,100 1,196,000 June 30 1,386,100 1,195,200 September 30 1,201,500 December 31 1,214,000 Medicare risk members enrolled at: March 31 276,600 268,600 June 30 281,200 268,200 September 30 268,400 December 31 270,800 Medicare supplement members enrolled at: March 31 144,100 178,600 June 30 139,000 168,000 September 30 161,100 December 31 153,600 Total members enrolled at: March 31 1,801,800 1,643,200 June 30 1,806,300 1,631,400 September 30 1,631,000 December 31 1,638,400
12 Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Humana Inc. Supplemental Consolidated Statement of Income (Dollars in millions except per share results)
1994 First Second Total Premiums: Commercial $ 480 $ 518 $ 998 Medicare risk 342 350 692 Medicare supplement 31 29 60 853 897 1,750 Interest 13 15 28 Other 3 5 8 869 917 1,786 Medical costs 703 736 1,439 Selling, general and administrative 102 111 213 Depreciation and amortization 12 12 24 817 859 1,676 Income from operations 52 58 110 Interest expense 1 1 2 Pretax income 51 57 108 Provision for income taxes 19 20 39 Net income $ 32 $ 37 $ 69 Earnings per share $ .20 $ .23 $ .43 Medical loss ratio 82.4% 81.9% 82.2% Administrative cost ratio 13.4% 13.6% 13.5% Note: Second quarter and the six-month results exclude the impact of the favorable settlement of tax disputes with the Internal Revenue Service and the write-down of a nonoperational asset.
13 Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (Continued) Humana Inc. Supplemental Consolidated Statement of Income (Dollars in millions except per share results)
1993 First Second Third Fourth Total Premiums: Commercial $ 426 $ 422 $ 428 $ 433 $1,709 Medicare risk 323 323 322 328 1,296 Medicare supplement 37 33 32 30 132 786 778 782 791 3,137 Interest 10 14 12 12 48 Other 2 3 2 3 10 798 795 796 806 3,195 Medical costs 662 660 654 654 2,630 Selling, general and administrative 93 91 91 93 368 Depreciation and amortization 12 12 12 11 47 767 763 757 758 3,045 Income from operations 31 32 39 48 150 Interest expense 2 2 1 2 7 Pretax income 29 30 38 46 143 Provision for income taxes 11 11 15 17 54 Net income $ 18 $ 19 $ 23 $ 29 $ 89 Earnings per share $ .11 $ .12 $ .15 $ .18 $ .56 Medical loss ratio 84.3% 84.8% 83.7% 82.7% 83.8% Administrative cost ratio 13.4% 13.1% 13.1% 13.3% 13.2%
14 Humana Inc. Part II: Other Information Item 1: Legal Proceedings A class action law suit styled Mary Forsyth, et al v. Humana Inc., et al, Case #CV-5-89-249-PMP (L.R.L.), was filed on March 29, 1989, in the United States District Court for the District of Nevada (the "Forsyth" case). The claims asserted by the plaintiffs included an ERISA count seeking $49,440,000 of damages plus approximately $15,396,000 of interest, a RICO count seeking $103,562,165 of damages (before trebling) plus approximately $31,800,000 of interest, and an antitrust count for an unspecified amount of damages which appeared to be similar to those sought in the RICO count. Despite allegations made by the plaintiffs, the Company considered the substance of these claims to be a dispute concerning the calculation of health insurance benefits and believed the claimed damages were greatly in excess of any possible recovery even if the plaintiffs were successful. On July 21, 1993, summary judgment was entered in favor of the Company on all counts, although the court granted the co-payer class until August 24, 1993, to file a third amended complaint in which its members could seek to recover the difference between their co-insurance payments and what those payments would have been if co-insurance obligations of the co-payer class had originally been based on the discounted payments made by Humana Health Insurance Company of Nevada to Sunrise Hospital and Medical Center, Las Vegas, Nevada, (now owned by Columbia/HCA Healthcare Corporation). On August 24, 1993, a third amended complaint styled Marietta Cade, et al v. Humana Health Insurance of Nevada, Inc., et al was filed seeking damages as described above. On January 28, 1994, summary judgment was entered in favor of plaintiffs on this third amended complaint and the Court subsequently approved a schedule of damages in the total amount of $1.6 million, plus $700,000 in prejudment interest. On July 1, 1994, the plaintiff's filed a Notice of Appeal to the Court of Appeals for the Ninth Circuit, seeking reinstatement of all previously dismissed counts. The Company believes the final resolution of this litigation will not have a material adverse effect on its operations or financial position. Items 2-3: None Item 4: Submission of Matters to a Vote of Security Holders (a) The regular annual meeting of stockholders of Humana Inc. was held in Louisville, Kentucky on May 26, 1994 for the purposes of electing the board of directors and voting on the proposals described below. (b) Proxies for the meeting were solicited pursuant to Section 14(a) of the Securities and Exchange Act of 1934 and there was no solicitation in opposition to management's solicitations. All of management's nominees for directors were elected. 15 Humana Inc. Part II: Other Information, continued Item 4: Submission of Matters to a Vote of Security Holders, continued (c) Four proposals were submitted to a vote of security holders as follows: (1) The stockholders approved the election of the following persons as directors of the Company: NAME FOR WITHHELD K. Frank Austen, M.D. 142,506,678 425,512 Michael E. Gellert 142,491,275 440,915 John R. Hall 139,564,398 3,367,792 David A. Jones 141,564,744 1,367,446 David A. Jones, Jr. 142,453,183 479,007 Irwin Lerner 142,442,802 489,388 W. Ann Reynolds, Ph.D. 142,482,163 450,027 Wayne T. Smith 142,506,439 425,751 (2) The stockholders approved with 119,434,831 affirmative votes, 22,131,135 negative votes, and 1,366,224 abstentions, the proposal to amend the Company's 1989 Stock Option Plan for Employees. (3) The stockholders approved with 106,870,801 affirmative votes, 34,987,015 negative votes and 1,074,374 abstentions, to amend the 1989 Stock Option Plan for Non-employee Directors. (4) The stockholders approved with 135,673,458 affirmative votes, 5,758,235 negative votes and 1,500,497 abstentions to approve a new Executive Management Incentive Compensation Plan. Item 5: Other Information (a) Ratio of Earnings to Fixed Charges The Company's ratio of earnings to fixed charges was 25.9 and 12.4 for the second quarter ended June 30, 1994 and 1993, respectively, and 23.2 and 12.1 for the six months ended June 30, 1994 and 1993, respectively. Item 6: Exhibits and Reports on Form 8-K (a) Exhibits Exhibit 12 - Statement re: Computation of Ratio of Earnings to Fixed Charges (b) Reports on Form 8-K A report on Form 8-K dated June 15, 1994, was filed by the Company stating the Company had received $71 million in tax refunds for settlement of certain income tax disputes with the Internal Revenue Service for the tax years 1988 through 1991.
16 Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. HUMANA INC. Date: August 15, 1994 /s/ James E. Murray James E. Murray Vice President and Controller (Principal Accounting Officer) Date: August 15, 1994 /s/ Arthur P. Hipwell Arthur P. Hipwell Senior Vice President and General Counsel 17
                                                                    Exhibit 12


                                  HUMANA INC.
                      RATIO OF EARNINGS TO FIXED CHARGES
         For the quarters and six months ended June 30, 1994 and 1993






                                
                                        Quarter Ended    Six Months Ended
                                           June 30,           June 30,   

                                                           
                                       1994      1993    1994       1993


Ratio of earnings to fixed charges     25.9      12.4    23.2       12.1



For the purpose of determining earnings in the calculation of the ratio of
earnings to fixed charges (the "Ratio"), earnings have been increased by the
provision for income taxes and fixed charges.  Fixed charges consist of
interest expense on borrowings and one-third (the proportion deemed
representative of the interest portion) of rents.  For purposes of calculating
the Ratio, 1994 earnings and interest expense exclude the impact of nonrecurring
items related to the favorable settlement of tax disputes with the Internal
Revenue Service and the write-down of a nonoperational asset.


18